Lannett Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Lannett Inc (LCINQ) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Lannett Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 300M vs 276,247M combined for tracked competitors (0.1% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+5.9% annualized vs trailing 12 months), vs decelerating (-18.3%) for its tracked peer group.
- Growth: Lannett Inc generated 1.4% revenue growth year over year in Q3 2023, vs -13.2% for its tracked competitors combined.
- Profitability: Its -127.7% net margin compares with 16.7% for the peer group.
- Peer revenue share: Lannett Inc accounted for 0.1% of combined revenue among its tracked peer group, up from 0.1% a year earlier.
- Peer differentiation: Revenue per employee of $2.59M compares with $0.98M for the peer group (2.6x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
LCINQ Sales vs. its Competitors, Q3 2023
Lannett Inc reported revenue growth of 1.41 % year on year in Q3 2023, above its competitors' combined revenue change of -13.20 %.
With a net margin of -127.69 %, Lannett Inc reported lower profitability than its competitors (16.70 %).
Lannett Inc generated 0.14 % of the combined sales of its peer group, up from 0.12 % a year earlier.
Lannett Inc vs. its Competitors, Q3 2023
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Lannett Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Lannett Company Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Lannett Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs 1.4% for Lannett Inc. Lannett Inc's share of combined industry revenue moved from 0.01% to 0.01%, a gain of 0.00 percentage points.
Lannett Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Lannett Company Inc | No | No | No | No |
| Competitors combined (52) | ||||
| Similar Growth & Profitability (8) | 12.50 % (1 of 8) | 37.50 % (3 of 8) | 25.00 % (2 of 8) | 12.50 % (1 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
LCINQ Stock Performance relative to its Competitors
LCINQ Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Spruce Biosciences Inc | 282.9% | Outperformed |
| 2 | Ironwood Pharmaceuticals inc | 282.9% | Outperformed |
| 3 | Eton Pharmaceuticals Inc | 282.9% | Outperformed |
| 4 | Avadel Pharmaceuticals Plc | 282.9% | Outperformed |
| 5 | Evoke Pharma Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Lannett Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Lannett Company Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Lannett Company Inc | 0.31 | 300.25 |
| Abbvie Inc | 471,581.88 | 64,386.00 |
| Amgen Inc | 227,462.72 | 38,095.00 |
| Pfizer Inc | 163,675.28 | 63,696.00 |
| Vertex Pharmaceuticals Inc | 134,661.38 | 12,587.20 |
| Regeneron Pharmaceuticals Inc | 79,738.50 | 15,534.70 |
| SUBTOTAL | 1,251,260.54 | 276,926.92 |
Sign in to see all competitors of Lannett Company Inc.
Sources: Lannett Company Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Lannett Company Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Lannett Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Keenova Therapeutics Plc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Lannett Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Lannett Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Pfizer Inc | U.S. Commercial Division 52.92 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Teva Pharmaceutical Industries Limited | United States Segment 41.09 % |
| Viatris Inc | Developed Markets 57.61 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Lannett Company Inc.
Lannett Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Lannett Company Inc | 0 | 2,588,336 | -2,364,586 |
| Abbvie Inc | 471,582 | 1,129,579 | 110,807 |
| Amgen Inc | 227,463 | 2,930,385 | 672,538 |
| Pfizer Inc | 163,675 | 849,280 | 58,267 |
| Vertex Pharmaceuticals Inc | 134,661 | 31,079,506 | 10,877,037 |
| Regeneron Pharmaceuticals Inc | 79,739 | 1,008,092 | 280,902 |
| PEERS TOTAL | 1,251,260 | 977,998 | 66,201 |
Sign in to see all peers for Lannett Company Inc.
Lannett Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Pfizer Inc | United States 58.91 % |
| Vertex Pharmaceuticals Inc | United States 61.68 % |
| Teva Pharmaceutical Industries Limited | Europe 30.49 % |
| Horizon Therapeutics Public Limited Company | United States 97.76 % |
| Perrigo Company Plc | United States 57.24 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Lannett Company Inc.
Lannett Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 16.62 % | 64.89 % (avg) | -48.3 pp |
| Operating Margin | -67.76 % | industry median | +85.2 pp |
| EBITDA Margin | -68.48 % | -7.21 % (avg) | -61.3 pp |
| Capital Intensity (Capex / Revenue) | - | 4.92 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Lannett Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 17.16 % | 48.46 % | -0.22 % | -33.75 % | -45.86 % | 56.14 % | 13.36 % | -26.39 % |
| Operating Margin | 43.28 % | 9.82 % | 25.04 % | -62.07 % | 30.03 % | -62.27 % | -23.83 % | -46.41 % |
| Return on Invested Capital | 15.13 % | 3.06 % | 8.07 % | -15.54 % | 5.18 % | -19.51 % | -16.28 % | -95.75 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Lannett Inc's Strategic Group Map
Every company in Lannett Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Lannett Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Lannett Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Lannett Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Lannett Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 85.2 points above the industry median.
- Return on equity 73.5 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+5.9% annualized vs trailing 12 months).
Weaknesses
No rule matched.
Opportunities
No rule matched.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-18.3% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Lannett Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Lannett Company Inc | 0.25 | 1.01 | - |
| Abbvie Inc | 0.16 | 0.75 | - |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Pfizer Inc | 0.04 | 1.24 | 0.71 |
| Vertex Pharmaceuticals Inc | 1.34 | 2.85 | - |
| Regeneron Pharmaceuticals Inc | 0.57 | 3.74 | 0.06 |
Sign in to see all peers for Lannett Company Inc.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Lannett Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Lannett Company Inc | Q1 2023 | +1.4 % | - |
| Abbvie Inc | Q2 2026 | +10.2 % | +284.3 % |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Pfizer Inc | Q2 2026 | +2.6 % | - |
| Vertex Pharmaceuticals Inc | Q2 2026 | +12.5 % | +6.5 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +16.7 % | -6.8 % |
| PEERS TOTAL | -0.3 % | - |
Sign in to see all peers for Lannett Company Inc.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Lannett Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Lannett Company Inc | Q1 2023 | -14.6 % | -44.0 % |
| Abbvie Inc | Q2 2026 | -1.3 % | +19.7 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Pfizer Inc | Q2 2026 | +8.3 % | -13.8 % |
| Vertex Pharmaceuticals Inc | Q2 2026 | +20.0 % | -23.0 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +109.2 % | +9.7 % |
Sign in to see all peers for Lannett Company Inc.
Lannett Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Lannett Company Inc | - | - | - |
| Abbvie Inc | 4.68% | 9.11% | - |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Pfizer Inc | 2.12% | 2.53% | 4.91% |
| Vertex Pharmaceuticals Inc | 16.88% | 19.97% | 23.31% |
| Regeneron Pharmaceuticals Inc | 10.60% | 11.83% | 13.81% |
Sign in to see all peers for Lannett Company Inc.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Lannett Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Lannett Company Inc | - | 0.00 |
| Abbvie Inc | 75.22 | 7.32 |
| Amgen Inc | 25.97 | 5.97 |
| Pfizer Inc | 37.66 | 2.57 |
| Vertex Pharmaceuticals Inc | 30.77 | 10.70 |
| Regeneron Pharmaceuticals Inc | 18.63 | 5.13 |
| PEERS AVERAGE | 67.82 | 4.52 |
Sign in to see all peers for Lannett Company Inc.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.